Correlation Between Genelux Common and SAB Biotherapeutics

Can any of the company-specific risk be diversified away by investing in both Genelux Common and SAB Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Genelux Common and SAB Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Genelux Common and SAB Biotherapeutics, you can compare the effects of market volatilities on Genelux Common and SAB Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Genelux Common with a short position of SAB Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Genelux Common and SAB Biotherapeutics.

Diversification Opportunities for Genelux Common and SAB Biotherapeutics

-0.74

Correlation Coefficient

Genelux Common  SAB Biotherapeutics

Pay attention - limited upside

The 3 months correlation between Genelux and SAB is -0.74. Overlapping area represents the amount of risk that can be diversified away by holding Genelux Common and SAB Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on SAB Biotherapeutics and Genelux Common is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Genelux Common are associated (or correlated) with SAB Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of SAB Biotherapeutics has no effect on the direction of Genelux Common i.e., Genelux Common and SAB Biotherapeutics go up and down completely randomly.

Pair Corralation between Genelux Common and SAB Biotherapeutics

Given the investment horizon of 90 days Genelux Common is expected to generate 0.85 times more return on investment than SAB Biotherapeutics. However, Genelux Common is 1.17 times less risky than SAB Biotherapeutics. It trades about 0.09 of its potential returns per unit of risk. SAB Biotherapeutics is currently generating about -0.13 per unit of risk. If you would invest  248.00  in Genelux Common on December 27, 2024 and sell it today you would earn a total of  72.00  from holding Genelux Common or generate 29.03% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Genelux Common  vs.  SAB Biotherapeutics

Genelux Common

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Genelux Common are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak essential indicators, Genelux Common showed solid returns over the last few months and may actually be approaching a breakup point.

SAB Biotherapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days SAB Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental drivers remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Genelux Common and SAB Biotherapeutics

The main advantage of trading using opposite Genelux Common and SAB Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Genelux Common position performs unexpectedly, SAB Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SAB Biotherapeutics will offset losses from the drop in SAB Biotherapeutics' long position.

The idea behind Genelux Common and SAB Biotherapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.